Hospital
Lake Cumberland Regional Hospital LLC
Lake Cumberland Regional Hospital LLC was paid $77.77M by Medicaid between Jan 2018 and Dec 2024, across 388 billing codes. Its largest line is 99285, emergency room visit (most serious) — 17% of everything it billed.
33Billing provider infoLAKE CUMBERLAND REGIONAL HOSPITAL LLC
SOMERSET, KY 42502
SOMERSET, KY 42502
33aNPI1619038247assigned 12/13/2006
33bProvider typeRural Acute Care Hospital
28Total paid$77.77M
24GClaims1,511,966
24DCodes billed388
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#3 of 10
Median peer was paid$23.35M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 197,476 | $11.89M | |
| 2019 | 193,592 | $10.91M | |
| 2020 | 187,448 | $10.61M | |
| 2021 | 233,930 | $11.10M | |
| 2022 | 238,819 | $10.13M | |
| 2023 | 260,161 | $12.38M | |
| 2024incomplete | 200,540 | $10.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 50,010 | 39,295 | $13.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 44,047 | 38,056 | $7.00M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.7% | 15,381 | 11,877 | $5.20M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.7% | 24,569 | 22,334 | $2.88M |
| 93458 | 3.7% | 3,194 | 1,887 | $2.88M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 6,436 | 5,005 | $2.51M |
| G0378 | Hospital observation service, per hour | 2.8% | 8,655 | 6,406 | $2.17M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 10,824 | 8,057 | $1.85M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 38,249 | 27,288 | $1.57M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.9% | 20,270 | 17,669 | $1.47M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 35,722 | 30,055 | $1.41M |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 1.7% | 1,797 | 1,450 | $1.33M |
376 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 23,230 | $1.15M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 3,701 | $997K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 10,889 | $992K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 21,267 | $826K |
| 80053 | Comprehensive metabolic panel | 1.0% | 107,936 | $782K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,533 | $734K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,897 | $733K |
| 36415 | Collection of venous blood by venipuncture | <1% | 149,010 | $708K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,193 | $689K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 28,171 | $688K |
| 62323 | <1% | 2,913 | $668K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 13,220 | $638K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14,992 | $638K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,637 | $593K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 87,688 | $565K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 7,115 | $522K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30,126 | $508K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 10,938 | $493K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,168 | $470K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,515 | $469K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 3,183 | $443K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,294 | $435K |
| 71250 | <1% | 3,641 | $422K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,699 | $401K |
| 99218 | <1% | 1,478 | $390K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,297 | $383K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,338 | $382K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 805 | $368K |
| 70498 | <1% | 1,487 | $360K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 7,010 | $350K |
| 74178 | <1% | 840 | $334K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 4,477 | $331K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,331 | $326K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 450 | $316K |
| 72131 | <1% | 1,807 | $310K | |
| 47563 | <1% | 432 | $303K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,975 | $295K |
| 70486 | <1% | 1,490 | $280K | |
| 73564 | <1% | 4,703 | $271K | |
| 84484 | <1% | 20,467 | $269K | |
| 72141 | <1% | 759 | $259K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 9,877 | $243K |
| 73630 | <1% | 4,082 | $239K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 8,967 | $238K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,122 | $236K |
| 93017 | <1% | 1,229 | $223K | |
| 72110 | <1% | 2,389 | $220K | |
| 70496 | <1% | 1,035 | $217K | |
| 73221 | <1% | 626 | $216K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,320 | $213K |
| 93971 | <1% | 1,794 | $210K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,438 | $208K |
| 74018 | <1% | 4,205 | $202K | |
| 73130 | <1% | 3,868 | $202K | |
| 73610 | <1% | 3,765 | $198K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 740 | $197K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 5,372 | $194K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,311 | $185K |
| 73030 | <1% | 4,241 | $181K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,165 | $172K |
| 95811 | <1% | 437 | $170K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,845 | $161K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 11,989 | $160K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,202 | $154K |
| 87428 | <1% | 5,718 | $146K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,940 | $146K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,701 | $145K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,585 | $144K |
| 73110 | <1% | 2,955 | $143K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,757 | $141K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 629 | $139K |
| C1769 | Guide wire | <1% | 3,045 | $137K |
| 72128 | <1% | 748 | $136K | |
| 88304 | <1% | 3,743 | $132K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,544 | $125K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17,784 | $123K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 4,682 | $121K |
| 81025 | <1% | 18,368 | $121K | |
| 78226 | <1% | 726 | $118K | |
| 76641 | <1% | 1,454 | $115K | |
| 83605 | <1% | 12,303 | $115K | |
| 83690 | <1% | 19,584 | $113K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,942 | $112K |
| 76770 | <1% | 1,336 | $111K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 15,294 | $110K |
| 76536 | <1% | 1,378 | $109K | |
| 62321 | <1% | 429 | $108K | |
| 76000 | <1% | 1,943 | $107K | |
| 96376 | <1% | 8,171 | $100K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 1,061 | $97K |
| 72100 | <1% | 1,961 | $97K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 210 | $96K |
| 73080 | <1% | 1,563 | $93K | |
| 0240U | <1% | 1,159 | $91K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,203 | $91K |
| 83735 | <1% | 14,885 | $86K | |
| 12001 | <1% | 1,729 | $82K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 158 | $82K |
| 82962 | <1% | 23,232 | $82K | |
| 81001 | <1% | 31,208 | $80K | |
| 77336 | <1% | 845 | $75K | |
| 97161 | <1% | 3,899 | $74K | |
| 87081 | <1% | 12,686 | $73K | |
| 73502 | <1% | 1,607 | $71K | |
| 83880 | <1% | 2,441 | $68K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,389 | $66K |
| 82803 | <1% | 3,525 | $66K | |
| 73590 | <1% | 1,489 | $66K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,518 | $65K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 669 | $65K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 2,280 | $65K |
| 93975 | <1% | 450 | $64K | |
| 80061 | Lipid panel | <1% | 7,052 | $61K |
| 71101 | <1% | 908 | $60K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 857 | $58K |
| 72170 | <1% | 1,578 | $56K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,307 | $55K |
| 88307 | <1% | 722 | $54K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 130 | $54K |
| 88312 | <1% | 1,537 | $53K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,807 | $52K |
| 77334 | <1% | 126 | $52K | |
| 84702 | <1% | 3,932 | $51K | |
| 80074 | <1% | 1,619 | $51K | |
| 87040 | <1% | 4,020 | $51K | |
| 73090 | <1% | 1,289 | $49K | |
| 77080 | <1% | 1,279 | $49K | |
| 85610 | <1% | 13,931 | $48K | |
| 88313 | <1% | 1,254 | $48K | |
| 64493 | <1% | 276 | $48K | |
| 71271 | <1% | 1,846 | $48K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,960 | $46K |
| 93880 | <1% | 358 | $43K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,223 | $43K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,238 | $43K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 563 | $42K |
| 85379 | <1% | 4,860 | $41K | |
| 84703 | <1% | 6,293 | $40K | |
| 87077 | <1% | 6,696 | $40K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,875 | $40K |
| 85730 | <1% | 8,593 | $38K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,789 | $38K |
| 87186 | <1% | 4,450 | $36K | |
| 76870 | <1% | 379 | $36K | |
| 72050 | <1% | 452 | $35K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,207 | $35K |
| 10060 | <1% | 464 | $34K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,830 | $34K |
| 87522 | Neg quan hep c or qual rna | <1% | 817 | $33K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,080 | $32K |
| 77412 | <1% | 319 | $32K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,079 | $32K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,773 | $29K |
| 87807 | <1% | 2,537 | $29K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,022 | $28K |
| C9600 | Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch | <1% | 113 | $28K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,264 | $28K |
| 86850 | <1% | 4,209 | $28K | |
| 81015 | <1% | 7,748 | $27K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,681 | $26K |
| 73560 | <1% | 1,174 | $26K | |
| 36600 | <1% | 2,343 | $25K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,004 | $25K |
| 86140 | <1% | 5,558 | $25K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,647 | $24K |
| 74246 | <1% | 206 | $24K | |
| 84146 | <1% | 1,347 | $24K | |
| 43249 | <1% | 129 | $24K | |
| 73140 | <1% | 582 | $23K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 114 | $22K |
| 87070 | <1% | 4,165 | $22K | |
| 90715 | <1% | 1,772 | $22K | |
| 82565 | <1% | 1,977 | $22K | |
| 70491 | <1% | 113 | $22K | |
| 12002 | <1% | 386 | $21K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 143 | $21K |
| 82607 | <1% | 1,822 | $20K | |
| 77300 | <1% | 146 | $19K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,136 | $19K |
| 12011 | <1% | 472 | $19K | |
| J7799 | Noc drugs, other than inhalation drugs, administered through dme | <1% | 782 | $19K |
| 80143 | <1% | 1,231 | $19K | |
| 76001 | <1% | 148 | $19K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,137 | $19K |
| C1874 | Stent, coated/covered, with delivery system | <1% | 18 | $18K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,233 | $18K |
| 72052 | <1% | 270 | $17K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,872 | $17K |
| 84439 | <1% | 2,385 | $16K | |
| 76801 | <1% | 421 | $16K | |
| 80179 | <1% | 1,071 | $16K | |
| 77066 | Tomosynthesis, mammo | <1% | 260 | $16K |
| 80324 | <1% | 559 | $16K | |
| 86901 | <1% | 5,814 | $15K | |
| 17250 | <1% | 363 | $15K | |
| 85027 | <1% | 2,998 | $15K | |
| 73562 | <1% | 264 | $15K | |
| 86900 | <1% | 6,086 | $15K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 369 | $14K |
| 84153 | <1% | 1,415 | $14K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,428 | $14K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,017 | $14K |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 524 | $13K |
| 88112 | <1% | 277 | $13K | |
| 84520 | <1% | 1,305 | $13K | |
| 72070 | <1% | 256 | $13K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 123 | $13K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 499 | $13K |
| 52356 | <1% | 13 | $13K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 212 | $12K |
| 88342 | <1% | 330 | $12K | |
| 82010 | <1% | 1,421 | $11K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 113 | $11K |
| 74300 | <1% | 107 | $11K | |
| 82728 | <1% | 1,006 | $10K | |
| 74420 | <1% | 108 | $10K | |
| 82550 | <1% | 1,565 | $10K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 239 | $10K |
| 74021 | <1% | 188 | $10K | |
| 0012A | <1% | 592 | $9K | |
| 97164 | <1% | 350 | $9K | |
| 97165 | <1% | 383 | $9K | |
| 72072 | <1% | 152 | $9K | |
| 85652 | <1% | 3,609 | $9K | |
| 93970 | <1% | 72 | $9K | |
| 74019 | <1% | 206 | $9K | |
| 84100 | <1% | 1,556 | $8K | |
| 73600 | <1% | 235 | $8K | |
| 97116 | <1% | 887 | $8K | |
| 82150 | <1% | 1,441 | $8K | |
| 96367 | <1% | 732 | $8K | |
| C1758 | Catheter, ureteral | <1% | 342 | $8K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 22 | $8K |
| 0011A | <1% | 666 | $8K | |
| 84403 | <1% | 357 | $8K | |
| 87205 | <1% | 1,761 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 82 | $7K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 323 | $7K |
| 78264 | <1% | 37 | $7K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 326 | $6K |
| J0583 | Injection, bivalirudin, 1 mg | <1% | 12 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,188 | $6K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 66 | $6K |
| 80076 | <1% | 466 | $6K | |
| 86255 | <1% | 398 | $6K | |
| 82784 | <1% | 509 | $6K | |
| C1726 | Catheter, balloon dilatation, non-vascular | <1% | 24 | $6K |
| 93925 | <1% | 51 | $6K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 349 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,829 | $6K |
| 72020 | <1% | 115 | $5K | |
| 64635 | <1% | 12 | $5K | |
| 94375 | <1% | 59 | $5K | |
| 84145 | <1% | 261 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 253 | $5K |
| 82248 | <1% | 868 | $5K | |
| A9510 | Technetium tc-99m disofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 197 | $5K |
| 20553 | <1% | 15 | $5K | |
| 83550 | <1% | 658 | $5K | |
| 86038 | <1% | 478 | $5K | |
| 83540 | <1% | 925 | $5K | |
| 76830 | Ultrasound, transvaginal | <1% | 48 | $4K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 555 | $4K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 649 | $4K |
| 88302 | <1% | 126 | $4K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,087 | $4K |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 54 | $4K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 25 | $4K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 83 | $4K |
| 73552 | <1% | 71 | $4K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 656 | $3K |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 225 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 425 | $3K |
| 83516 | <1% | 142 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 91 | $3K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 24 | $3K |
| 77280 | <1% | 44 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 70 | $3K |
| 36430 | <1% | 27 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 367 | $3K |
| 80305 | <1% | 251 | $2K | |
| 92526 | <1% | 50 | $2K | |
| 93660 | <1% | 17 | $2K | |
| 93922 | <1% | 13 | $2K | |
| 83970 | <1% | 44 | $2K | |
| 86308 | <1% | 465 | $2K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 34 | $2K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 123 | $2K |
| 82746 | <1% | 155 | $2K | |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 344 | $2K |
| 73060 | <1% | 58 | $2K | |
| 86706 | <1% | 201 | $2K | |
| C1781 | Mesh (implantable) | <1% | 16 | $2K |
| 82042 | <1% | 364 | $2K | |
| 82308 | <1% | 81 | $2K | |
| 95816 | <1% | 19 | $2K | |
| 74230 | <1% | 52 | $2K | |
| 83520 | <1% | 89 | $2K | |
| 82103 | <1% | 131 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 259 | $2K |
| 88300 | <1% | 88 | $1K | |
| 87210 | <1% | 314 | $1K | |
| 82570 | <1% | 348 | $1K | |
| 76642 | <1% | 15 | $1K | |
| 83010 | <1% | 76 | $1K | |
| 94729 | <1% | 27 | $1K | |
| 29126 | <1% | 30 | $1K | |
| 94727 | <1% | 27 | $1K | |
| C1765 | Adhesion barrier | <1% | 22 | $1K |
| 84550 | <1% | 265 | $1K | |
| 97162 | <1% | 13 | $1K | |
| 73100 | <1% | 37 | $1K | |
| 85007 | <1% | 357 | $1K | |
| 81596 | <1% | 25 | $1K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 27 | $1K |
| 87899 | <1% | 43 | $1K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 63 | $1K |
| 87340 | <1% | 93 | $924.79 | |
| 83615 | <1% | 213 | $918.37 | |
| 86708 | <1% | 83 | $906.36 | |
| 99499 | <1% | 73 | $900.75 | |
| 83883 | <1% | 73 | $898.50 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 40 | $882.65 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,835 | $861.37 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 35 | $715.02 |
| 87075 | <1% | 38 | $710.41 | |
| 82104 | <1% | 61 | $694.78 | |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $688.12 |
| 70360 | <1% | 15 | $648.05 | |
| A9270 | Non-covered item or service | <1% | 2,143 | $622.76 |
| 82272 | <1% | 173 | $591.37 | |
| 82140 | <1% | 54 | $581.28 | |
| 82247 | <1% | 132 | $517.08 | |
| 36416 | <1% | 105 | $481.37 | |
| 86703 | <1% | 73 | $445.26 | |
| 96368 | <1% | 37 | $437.06 | |
| 87339 | <1% | 32 | $433.01 | |
| 90714 | <1% | 41 | $427.56 | |
| 83874 | <1% | 47 | $393.42 | |
| 80069 | <1% | 64 | $375.17 | |
| 94200 | <1% | 27 | $345.57 | |
| 85576 | <1% | 17 | $332.29 | |
| 84436 | <1% | 57 | $322.37 | |
| 86780 | <1% | 30 | $290.92 | |
| 86677 | <1% | 13 | $288.04 | |
| 87045 | <1% | 29 | $287.26 | |
| 86803 | <1% | 26 | $270.05 | |
| 11045 | <1% | 38 | $249.93 | |
| 86696 | <1% | 12 | $248.86 | |
| 84402 | <1% | 15 | $240.75 | |
| 82390 | <1% | 25 | $218.80 | |
| 86381 | <1% | 15 | $193.94 | |
| C1766 | Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away | <1% | 18 | $187.43 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 42 | $179.20 |
| 80320 | <1% | 34 | $176.83 | |
| 86704 | <1% | 12 | $169.44 | |
| 80164 | <1% | 15 | $150.52 | |
| 86695 | <1% | 12 | $144.81 | |
| 82310 | <1% | 43 | $131.02 | |
| 87015 | <1% | 13 | $122.31 | |
| 88311 | <1% | 12 | $121.28 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 75 | $114.69 |
| 86015 | <1% | 13 | $111.37 | |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | <1% | 19 | $110.24 |
| G0008 | Administration of influenza virus vaccine | <1% | 18 | $103.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 567 | $92.19 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 13 | $83.43 |
| 87400 | <1% | 124 | $48.25 | |
| 86592 | <1% | 13 | $45.94 | |
| 91301 | <1% | 1,278 | $27.46 | |
| 80050 | General health panel | <1% | 27 | $10.26 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | <1% | 313 | $0.05 |
| 64636 | 0% | 12 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 66 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 16 | $0.00 |
| 64494 | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.